Churg-Strauss syndrome: Evidence for disease subtypes?

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 21-28

  Pagnoux, Christian ^a   Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ANCA; Asthma; Churg Strauss syndrome; Eosinophils; Vasculitis

Indexed keywords

MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ALLERGIC RHINITIS; ASTHMA; CHURG STRAUSS SYNDROME; DISEASE CLASSIFICATION; HEART DISEASE; HUMAN; KIDNEY DISEASE; LUNG HEMORRHAGE; LUNG INFILTRATE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RARE DISEASE; REVIEW; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNITY; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PEROXIDASE;

EID: 73649124628     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328333390b     Document Type: Review

References (117)

1. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8:179-189.
2. Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19:191-207.
3. Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg- Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46:1329-1337.
4. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg- Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92-99.
5. Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17:364-368.
6. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25-32.
7. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587-594.
8. Grau RG. Churg-Strauss syndrome: 2005-2008 update. Curr Rheumatol Rep 2008; 10:453-458.
9. Lhote F. Churg-Strauss syndrome [in French]. Presse Méd 2007; 36:875-889.
10. Vaglio A, Casazza I, Grasselli C, et al. Churg-Strauss syndrome. Kidney Int 2009. [Epub ahead of print]
11. Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355-366.
12. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926-2935.
13. Sablé -Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-638.
14. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
15. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65-81.
16. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 2005; 1051:121-131.
17. Guilpain P, Auclair JF, Tamby MC, et al. Serum eosinophil cationic protein: a marker of disease activity in Churg-Strauss syndrome. Ann N Y Acad Sci 2007; 1107:392-399.
18. Manger BJ, Krapf FE, Gramatzki M, et al. IgE-containing circulating immune complexes inChurg-Strauss vasculitis.Scand J Immunol1985; 21:369-373.
19. Ishii T, Fujita T, Matsushita T, et al. Establishment of experimental eosinophilic vasculitis by IgE-mediated cutaneous reverse passive Arthus reaction. Am J Pathol 2009; 174:2225-2233.
20. Zwerina J, Axmann R, Manger B, Schett G. The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum 2009; 60:626-627.
21. Pagnoux C, Guilpain P, Hauser T, Guillevin L. Churg-Strauss syndrome and leukotriene modifying agents. Clin Pulmon Med 2004; 11:349-354.
22. Beasley R, Bibby S, Weatherall M. Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander? Thorax 2008; 63:847-849.
23. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63:677-682.
24. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest 2009; 136:507-518.
25. Pué chal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008; 19:364-366.
26. Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008; 121:253-254.
27. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355:1281-1282.
28. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26-37.
29. Lanham JG, Cooke S, Davies J, Hughes GR. Endomyocardial complications of the Churg-Strauss syndrome. Postgrad Med J 1985; 61:341-344.
30. Pagnoux C, Guillevin L. Cardiac involvement in small and medium-sized vessel vasculitides. Lupus 2005; 14:718-722.
31. Baldini C, Della Rossa A, Grossi S, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre [in Italian]. Reumatismo 2009; 61:118-124.
32. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg- Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236-243.
33. Guilpain P, Cohen P, Pagnoux C, et al. Severe cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2007; 56:S771.
34. Marmursztejn J, Vignaux O, Cohen P, et al. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss Syndrome: a crosssectional study in 20 patients. Clin Exp Rheumatol 2009; 27:S70-S76.
35. Smedema JP, van Paassen P, van Kroonenburgh MJ, et al. Cardiac involvement of Churg-Strauss syndrome demonstrated by magnetic resonance imaging. Clin Exp Rheumatol 2004; 22:S75-S78.
36. Petersen SE, Kardos A, Neubauer S. Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance. Heart 2005; 91:e9.
37. Alter P, Maisch B. Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. Int J Cardiol 2006; 108:112-113.
38. Caudron J, Bauer F, Dacher JN. Cardiac magnetic resonance demonstrates the three-layer involvement in Churg-Strauss syndrome. Eur Heart J 2008; 29:2952.
39. Wassmuth R, Gobel U, Natusch A, et al. Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. J Card Fail 2008; 14:856-860.
40. Bhagirath KM, Paulson K, Ahmadie R, et al. Clinical utility of cardiac magnetic resonance imaging in Churg-Strauss syndrome: case report and review of the literature. Rheumatol Int 2009; 29:445-449.
41. Hansch A, Pfeil A, Rzanny R, et al. First-pass myocardial perfusion abnormalities in Churg-Strauss syndrome with cardiac involvement. Int J Cardiovasc Imaging 2009; 25:501-510.
42. Mavrogeni S, Manoussakis MN, Karagiorga TC, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum 2009; 61:1121-1129.
43. Esposito A, De Cobelli F, Belloni E, et al. Magnetic resonance imaging of a hypereosinophilic endocarditis with apical thrombotic obliteration in Churg- Strauss syndrome complicated with acute abdominal aortic embolic occlusion. Int J Cardiol 2009. [Epub ahead of print]
44. Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation 2008; 117:1745-1749.
45. Morita H, Yokoyama I, Yamada N, et al. Usefulness of 18FDG/13N-ammonia PET imaging for evaluation of the cardiac damage in Churg-Strauss syndrome. Eur J Nucl Med Mol Imaging 2004; 31:1218.
46. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284-290.
47. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611-619.
48. Girard T, Mahr A, Noël LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40:147-151.
49. Tervaert JW, Kallenberg CG. Antimyeloperoxidase antibodies in Churg- Strauss syndrome. J Neurol 1993; 240:449-450.
50. Tervaert JW, Stegeman CA, Kallenberg CG. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:241-245.
51. Terrier B, Saadoun D, Sene D, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in ANCA-associated vasculitides. Ann Rheum Dis 2009; 68:1564-1571.
52. Tsukadaira A, Okubo Y, Kitano K, et al. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc 1999; 20:39-44.
53. Termeer CC, Simon JC, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch Dermatol 2001; 137:136-138.
54. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 h after allergen challenge. Am J Respir Cell Mol Biol 2001; 24:682-687.
55. Polzer K, Karonitsch T, Neumann T, et al. Eotaxin-3 is involved in Churg- Strauss syndrome: a serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008; 47:804-808.
56. Mitsuyama H, Matsuyama W, Watanabe M, et al. Increased expression of TRAIL receptor 3 on eosinophils in Churg-Strauss syndrome. Arthritis Rheum 2007; 56:662-673.
57. Carbonari M, Tedesco T, Del Porto P, et al.Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: consequences for immunopathogenesis. Clin Exp Immunol 2000; 120:454-462.
58. Tsurikisawa N, Saito H, Tsuburai T, et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008; 122:610-616.
59. Wieczorek S, Hellmich B, Gross WL, Epplen JT. Associations of Churg- Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008; 58:329-330.
60. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56:3159-3166.
61. Jagiello P, Gencik M, Arning L, et al. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 2004; 114:468-477.
62. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292-1302.
63. Klion AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematol Am Soc Hematol Educ Program Book 2005; 1:209-214.
64. Hellmich B, Holl-Ulrich K, Merz H, Gross WL. Hypereosinophilic syndrome and Churg-Strauss syndrome: is it clinically relevant to differentiate these syndromes? [in German]. Internist (Berl) 2008; 49:286-296.
65. Cools J, Stover EH, Wlodarska I, et al. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004; 11:51-57.
66. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22:1999-2010.
67. Loules G, Kalala F, Giannakoulas N, et al. FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC Blood Disord 2009; 9:1-7.
68. Peros-Golubicic T, Smojver-Jezek S. Hypereosinophilic syndrome: diagnosis and treatment. Curr Opin Pulm Med 2007; 13:422-427.
69. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005; 114:52-60.
70. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14-22.
71. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007; 2:37.
72. Patnaik MM, Tefferi A. Molecular diagnosis of myeloproliferative neoplasms. Expert Rev Mol Diagn 2009; 9:481-492.
73. Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosomenegative chronic myeloproliferative disorders. Semin Thromb Hemost 2006; 32:307-340.
74. SteensmaDP,DewaldGW,LashoTL, et al.TheJAK2V617Factivatingtyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207-1209.
75. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005; 60:841-857.
76. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58:586-594.
77. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290-1297.
78. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763-771.
79. Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome: successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22:S52-S61.
80. Gayraud M, Guillevin L, Le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666-675.
81. Jayne DR, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44. (Pubitemid 36765101)
82. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-2168.
83. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006; 65:1116-1117.
84. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65:557-559.
85. PepperRJ, FabreMA, PavesioC, et al. Rituximab is effective in the treatment of refractoryChurg-Strauss syndrome and is associated with diminished Tcell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104-1105.
86. Roccatello D, Baldovino S, Alpa M, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26:S67-S71.
87. Bouldouyre MA, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68:606.
88. Levings MK, Sangregorio R, Galbiati F, et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001; 166:5530-5539.
89. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370-374.
90. Mouthon L, Guillevin L. Interferon-alpha in corticosteroid-resistant asthma and Churg-Strauss syndrome. Allergy 2003; 58:1244-1246.
91. Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg- Strauss syndrome. Expert Opin Pharmacother 2004; 5:25-35.
92. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferonalpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26:S35-S40.
93. Simon HU, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroidresistant asthma. Allergy 2003; 58:1250-1255.
94. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991; 99:557-561.
95. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215-1228.
96. Antoniu SA. Imatinib mesylate for the treatment of hypereosinophilic syndromes. Curr Opin Investig Drugs 2006; 7:980-984.
97. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179.
98. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 2009; 33:1127-1129.
99. Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 2009; 33:837-839.
100. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143:707-715.
101. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1-16.
102. Salem Z, Zalloua PA, Chehal A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J 2003; 4:410-412.
103. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, antiinterleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D 2008; 9:125-130.
104. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 2006; 533:302-307. (Pubitemid 43340021)
105. Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory 'forme fruste' of Churg-Strauss syndrome. Thorax 2008; 63:747-748.
106. Giavina-Bianchi P, Agondi R, Kalil J. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol 2008; 146:176.
107. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119:1279. (Pubitemid 46654183)
108. Spina MF, Miadonna A. Role of omalizumab and steroids in Churg-Strauss syndrome. J Allergy Clin Immunol 2009; 124:600-601.
109. Giavina-Bianchi P, Giavina-Bianchi M, Agondi RC, Kalil J. Anti-IgE in Churg- Strauss syndrome. Thorax 2009; 64:272.
110. Tiliakos At, Shaia S, Hostoffer R, Kent L. The use of infliximab in a patient with steroid-dependent Churg-Strauss syndrome. J Clin Rheumatol 2004; 10:96-97.
111. Arbach O, Gross WL, Gause A. Treatment of refractory Churg- Strausssyndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206: 496-501.
112. Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63:1649-1654.
113. Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92:80-87.
114. Levy Y, George J, Fabbrizzi F, et al. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med J 1999; 92:412-414.
115. Kallenberg CG. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum 2005; 52:2589-2593.
116. Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? Ann Intern Med 2005; 143: 683-685.
117. Langford CA, Hoffman GS. Intravenous immunoglobulin in Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2008; 58:2211-2212.